These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19897682)

  • 21. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
    Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty.
    Weise M; Flor A; Barnes KM; Cutler GB; Baron J
    J Clin Endocrinol Metab; 2004 Jan; 89(1):103-7. PubMed ID: 14715835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
    J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty.
    van Gool SA; Kamp GA; Visser-van Balen H; Mul D; Waelkens JJ; Jansen M; Verhoeven-Wind L; Delemarre-van de Waal HA; de Muinck Keizer-Schrama SM; Leusink G; Roos JC; Wit JM
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1402-8. PubMed ID: 17284626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final adult height in children with central precocious puberty - a retrospective study.
    Knific T; Lazarevič M; Žibert J; Obolnar N; Aleksovska N; Šuput Omladič J; Battelino T; Avbelj Stefanija M
    Front Endocrinol (Lausanne); 2022; 13():1008474. PubMed ID: 36531464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
    Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
    Heger S; Partsch CJ; Sippell WG
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
    Sørensen K; Andersson AM; Skakkebaek NE; Juul A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study.
    Saggese G; Federico G; Barsanti S; Fiore L
    J Clin Endocrinol Metab; 2001 May; 86(5):1900-4. PubMed ID: 11344181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
    Guaraldi F; Beccuti G; Gori D; Ghizzoni L
    Eur J Endocrinol; 2016 Mar; 174(3):R79-87. PubMed ID: 26466612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty].
    Wang CL; Liang L; Liu PN; Jin XJ; Chen LQ; Yang F; Lian Q; Chen RM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Jan; 16(1):25-30. PubMed ID: 24461173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can the TW3 bone age determination method provide additional criteria for growth hormone treatment in adopted girls with early puberty? A comparison of the Tanner-Whitehouse 3 method with the Greulich-Pyle and the Tanner-Whitehouse 2 methods.
    Proos LA; Lönnerholm T; Jonsson B; Tuvemo T
    Horm Res Paediatr; 2010; 73(1):35-40. PubMed ID: 20190538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Beneficial Effect of Combined GH/GnRHa Therapy in Increasing Adult Height Outcome in Children With ISS.
    Lazar L; Levy S; Oron T; Meyerovitch J; de Vries L; Shalitin S; Tenenbaum A; Phillip M; Lebenthal Y
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3287-3295. PubMed ID: 30912806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.